![]() |
|
|
Vol. 303, Issue 3, 1061-1066, December 2002
Department of Pharmacology and Experimental Therapeutics (P.E., N.C., K.K., S.B., D.T., T.C.T), Department of Surgical Research (R.C.), Department of Anatomy and Cell Biology (S.J.), and Department of Internal Medicine (T.C.T.), Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts
| |
Abstract |
|---|
|
|
|---|
Stress activates the hypothalamic-pituitary-adrenal axis through release of corticotropin releasing hormone (CRH), leading to production of glucocorticoids that down-regulate immune responses. Acute stress, however, also has proinflammatory effects that seem to be mediated through the activation of mast cells. Stress and mast cells have been implicated in the pathophysiology of various inflammatory conditions, including some in the central nervous system, such as multiple sclerosis in which disruption of the blood-brain barrier (BBB) precedes clinical symptoms. We previously showed that acute restraint stress increases rat BBB permeability to intravenous 99Tc gluceptate and that administration of the "mast cell stabilizer" disodium cromoglycate (cromolyn) inhibits this effect. In this study, we show that the CRH-receptor antagonist Antalarmin blocks stress-induced 99Tc extravasation, whereas site-specific injection of CRH in the paraventricular nucleus (PVN) of the hypothalamus mimics acute stress. This latter effect is blocked by pretreatment of the PVN with cromolyn; moreover, restraint stress cannot disrupt the BBB in the diencephalon and cerebellum of W/Wv mast cell-deficient mice. These results demonstrate that CRH and mast cells are involved in regulating BBB permeability and, possibly, brain inflammatory disorders exacerbated by acute stress.
| |
Introduction |
|---|
|
|
|---|
The
blood-brain barrier (BBB) is made up of brain microvessel endothelial
cells (Johansson, 1990
), astroglia, pericytes, perivascular macrophages, and basal lamina. Brain microvessel endothelial cells are
characterized by tight intracellular junctions restricting passage of
most molecules from the circulation to the brain. The protective
function of the BBB can be altered during various disease states of the
central nervous system, specifically during cerebral inflammation (De
Vreis et al., 1997
) such as that present in multiple sclerosis (MS)
(Kermode et al., 1990
). Brain leukocyte infiltration in MS (Smith and
Weiner, 1997
) follows a decrease in the integrity of the BBB (Kermode
et al., 1990
). BBB permeability may be affected by acute stress that
seems to exacerbate symptoms in relapsing-remitting MS (Mei-Tal et al.,
1970
; Goodin et al., 1999
).
Stress activates the hypothalamic-pituitary-adrenal (HPA) axis through
the release of corticotropin-releasing hormone (CRH) leading to
secretion of catecholamines and glucocorticoids; these, in turn,
down-regulate the immune response (Chrousos, 1995
). CRH is synthesized
predominantly in the paraventricular nucleus (PVN) and mediates its
effects through at least three types of receptors (CRHR): CRHR-1,
CRHR-2
, and CRHR-2
. These are also present elsewhere in the brain
indicating that CRH or structurally related compounds such as
urocortin, which has stronger affinity for the CRH-R2 (Vaughan et al.,
1995
), might have paracrine actions. Stress, however, also worsens a
number of neuroinflammatory disorders (Rosch, 1979
), and CRH also has
proinflammatory effects (Karalis et al., 1991
), apparently mediated
through mast cell activation (Theoharides et al., 1998
). We recently
reported that acute restraint stress increases BBB permeability in
rats, an action dependent on mast cell activation because it was
blocked by the "mast cell stabilizer" disodium cromoglycate
(cromolyn) (Esposito et al., 2001
). Acute restraint stress was shown to
induce intracranial rat mast cell activation and elevate cerebrospinal
fluid levels of rat mast cell protease (RMCP-I), actions that were
CRH-dependent (Theoharides et al., 1995
). Moreover, CRH (Theoharides et
al., 1998
) induced mast cell degranulation and Evans blue extravasation in rodent skin, a phenomenon duplicated by acute restraint stress and
also blocked by Antalarmin (Singh et al., 1999
).
Mast cells are ubiquitous in the body and are critical for allergic
reactions, but they also secrete numerous cytokines (Galli, 1993
;
Metcalfe et al., 1997
). Increasing evidence indicates that mast cells
may also be involved in neuroimmune interactions (Church et al., 1989
;
Rozniecki et al., 1999
), including neuroinflammatory processes
(Theoharides, 1996
). In the brain, mast cells are predominantly located
perivascularly, especially in the thalamus and hypothalamus (Ibrahim,
1974
; Pang et al., 1996
). As many mast cell mediators are vasoactive,
mast cells may regulate the BBB (Theoharides, 1990
), a proposal
supported by findings that a chemical trigger of mast cells, compound
48/80, increased BBB permeability in the mast cell rich habenula
of pigeons (Zhuang et al., 1996
).
In this study, we show that BBB permeability induced by acute restraint stress involves CRH because it is blocked by pretreatment with Antalarmin and is mimicked by site-directed CRH injection in the hypothalamus. We also provide further support that the stress-induced increase in BBB permeability requires mast cells since it is absent in mast cell-deficient mice.
| |
Materials and Methods |
|---|
|
|
|---|
Restraint Stress and Indicator Extravasation. Male, Sprague-Dawley, 300-g rats (Charles River, Willmington, MA) were kept on a 14:10-h dark/light cycle and were provided food and water ad labium. Animals were first anesthetized with one i.p. injection (0.3 ml) of a mixture of ketamine and xylazine (1.0 and 0.02 ml, respectively, of 100 mg/ml each). They were then cannulated via the jugular vein. In certain cases, guide cannulas (Plastic One, Roanoke, VA) were inserted into the paraventricular region of the hypothalamus as described later Animals were handled daily to check on the guide cannula and i.v. catheter and to familiarize them with the investigators.
The morning of the experiment (9 AM-12 PM), animals were injected with 500 µCi of 99Tc gluceptate, which was prepared as follows. Gluceptate (DRAXIMAGE, Inc., Kirkland, Quebec, Canada), a D-glycerol-D-gluco-heptonate complex was obtained from Synchor Pharmacy (Woburn, MA). The gluceptate was then mixed with 99Tc (DuPont, Wilmington, DE) the morning of the experiment. Binding to gluceptate prevents 99Tc from escaping the circulation and constitutes a good marker of vascular permeability and extravasation in brain parenchyma (Jacobson et al., 1989Use of W/Wv Mice in 99Tc Extravasation Experiments. Male C57BL mice, as well as W/Wv mast cell-deficient mice (WBB 6F1/J-W/Wv) and their wild-type controls (8 weeks old), were obtained from Jackson Labs (Bar Harbor, ME) and were kept four per cage. Mice were handled daily for 5 days to acclimate them to the investigators. On the morning of the experiment, mice were injected with 0.2 ml of 75 µCi 99Tc via the tail vein. Following injection, mice were either placed in their home cages or immobilized for 30 min. After this time, mice were perfused and decapitated, and their brains were removed as described for rats above. It was estimated that 10 mice per group were necessary for 50% increase in BBB permeability of the diencephalon due to stress.
Site-Specific Injections.
Following anesthesia, rats were
placed in the stereotaxic apparatus and prepared as described above.
Guide cannulas (Plastic One) were inserted into the paraventricular
region of the diencephalon as follows: 1.80 mm lateral and 1.90 mm
posterior from Bregma, at a 10° angle and 8.9 mm deep (Paxinos and
Watson, 1986
). The animals were allowed to recover in the animal
facility for 14 days before use. Animals were handled daily to check
the guide cannula and i.v. catheter and to familiarize them with the
investigators. To determine whether exogenous CRH could mimic the
effect of stress on BBB permeability, we administered CRH centrally by
an ipsilateral site injection in the PVN of the hypothalamus. The
injection was unable to target any specific subnuclei because of the
size of the cannula. We chose to inject the PVN because most of the
endogenous CRH is localized in this area and mast cells are plentiful
in the median evidence, close to CRH positive neurons (Pang et al., 1996
). Animals with implanted guide cannulas received 1 µl of 1 mM
CRH (5 µg) or 1 µl 0.9% NaCl directly in the PVN. Animals remained
in their cages for 30 min and were not restrained.
Corticosterone Measurements. Corticosterone was measured in the serum of both rats and mice using an ImmuChem double-antibody corticosterone 125-RIA kit (ICN Biomedicals, Costa Mesa, CA).
Statistics.
Due to the short half-life of
99Tc (about 6 h), it was impossible to
assure delivery of exactly the same dose of 99Tc
each day the experiment was performed. Therefore, it was necessary to
express the difference of counts in stressed animals as a percentage of
the controls from each day [(experimental-control)/mean control] × 100. We analyzed the data generated in two ways: 1) to establish whether any change from baseline was statistically significant from
zero, values were compared using a one-sample t test; and 2)
to determine whether the change that occurred within treatment groups
(e.g., with and without Antalarmin) was significant, values were
compared using the nonparametric Mann-Whitney U test. For all tests of significance,
was set at 0.05.
| |
Results |
|---|
|
|
|---|
Effect of Restraint Stress on Serum Corticosterone.
Serum
corticosterone levels were increased due to restraint stress in all
experiments. Corticosterone levels in rats increased from 131.1 ± 36.8 to 222.0 ± 55.9 ng/ml with 30 min of restraint stress, as
previously published (Esposito et al., 2001
). Control C57BL mice had
55.0 ± 24.9 ng/ml that increased to 386.4 ± 57.2 ng/ml
after 30 min restraint stress. The W/Wv mice had
a similar response to stress with levels increasing from 40.5 ± 35.9 to 317.3 ± 47.0 ng/ml within 30 min (Huang et al., 2002
).
Therefore, any observed differences in BBB permeability in these mast
cell-deficient mice were not due to differences in HPA axis activation.
Effect of Antalarmin on 99Tc Extravasation.
BBB
permeability was assessed by quantitating extravasation of
99Tc in brain parenchyma of the following four
different brain areas to investigate any regional differences:
diencephalon, cerebellum, cerebral cortex, and brainstem. Acute stress
by restraint for 30 min increased BBB permeability in all brain
regions, with the maximal increase of 210 ± 130% noted in the
cerebellum and the diencephalon that were statistically different from
control (Fig. 1); the increase in the
cortex, however, was not statistically significant. Pretreatment with
Antalarmin (given i.v. at dosages of 1.2, 4, or 10 mg/kg body weight
for 60 min before stress) reduced this effect in a dose-dependent
manner in all brain regions studied (Fig. 1). Maximal reduction of
99Tc extravasation was observed in the
diencephalon with the values dropping from 170 ± 120% during
stress to 7 ± 25% after pretreatment with 10 mg of Antalarmin.
|
Effect of CRH Injected into the PVN on 99Tc
Extravasation.
We investigated whether intracranial administration
of CRH could mimic the increased BBB permeability induced by acute
stress. CRH first administered intraventricularly did not increase BBB permeability (results not shown). We then injected CRH into the PVN
through a guide cannula implanted using stereotaxic co-ordinates. Histology of the injection site showed little pathology; the presence of a well organized compartment surrounding the track of the cannula suggests the tissue had recovered from the initial trauma caused by the
implantation surgery (Fig. 2A). Figure 2B
shows the location of the guide cannula tip (in the area of the PVN) in
relation to the third ventricle. Site directed injection of CRH in the PVN increased BBB permeability about 50% in the diencephalon, cerebellum and cortex but not in the brainstem (Fig.
3).
|
|
Effect of Cromolyn Injected into PVN on CRH-Induced 99Tc Extravasation. To further investigate the involvement of mast cells, animals were injected with cromolyn into the PVN 30 min before CRH injection. Pretreatment with cromolyn reduced 99Tc extravasation significantly only in the diencephalon (Fig. 3).
Effect of Acute Stress on 99Tc Extravasation in the
Brain of W/Wv Mast Cell-Deficient Mice.
W/Wv mast cell-deficient mice were shown to
increase their serum corticosterone levels in response to 30 min of
restraint stress equally to their wild-type controls (see above).
Nevertheless, there was no 99Tc extravasation due
to acute stress in any brain area, except for the brainstem, compared
with their wild-type controls (Fig. 4).
These results indicate that mast cells are critical for acute stress to
increase BBB permeability.
|
| |
Discussion |
|---|
|
|
|---|
To our knowledge, this is the first time that CRH is shown to be
involved in BBB permeability induced by acute stress, which is
supported by the fact that stress-induced increase in BBB is blocked by
the CRHR antagonist Antalarmin and that it is mimicked by the
administration of CRH in the PVN of the hypothalamus. Although CRH is
typically thought to be expressed in the hypothalamus, it is also
detected in extrahypothalamic sites; these include the central and
medial nuclei of the amygdala, the olfactory bulb, the cortex, and the
deep cerebellar nuclei of the cerebellum (Dieterich et al., 1997
).
CRH activates the HPA, but may have other central effects because CRHR
are expressed in other brain parts. CRHR-1 expression is highest in the
cerebral cortex, striatum, amygdala, and cerebellum (Chalmers et al.,
1996
), whereas CRHR-2 is present mostly in subcortical structures such
as the lateral septal nucleus, several nuclei of the hypothalamus, and
the choroid plexus (Chalmers et al., 1996
). It was previously
suggested that CRH may be involved in dura mast cell activation in
response to restraint stress (Theoharides et al., 1995
) and skin mast
cell activation and vascular permeability (Theoharides et al., 1998
)
since these effects were blocked by the CRHR-antagonist Antalarmin
(Theoharides et al., 1998
; Rozniecki et al., 1999
). Antalarmin has
higher selectivity for the CRHR-1 (Webster et al., 1996
) and has been
shown to block stress-induced behavioral effects (Deak et al., 1999
).
Even though site injection of CRH increased BBB permeability, when CRH
was administered i.c.v., it was ineffective. It is possible that CRH is
cleared from the ventricular system before reaching the brain
parenchyma; for instance, a saturable efflux allows CRH to be
transported of the brain into the blood (Martins et al., 1997
). The
fact that CRH administered into the PVN increased 99Tc extravasation in other brain regions
(cerebellum, brainstem, and cortex) suggests several different
possibilities: 1) CRH could diffuse outside the diencephalon and have
local (paracrine) effects; 2) CRH could affect neurons in the
diencephalon that project into other regions of the brain, possibly
leading to neuronal release of vasoactive compounds such as substance P
or TNF-
; and 3) mediators from activated diencephalic mast cells
could have effects elsewhere. This last possibility is less likely due
to the fact that pretreatment with cromolyn injected directly into the
PVN-blocked 99Tc extravasation only in the
diencephalon. Cromolyn either may not be able to diffuse to all areas
where CRH reaches or may not block mast cell activation completely,
especially since it does not block all types of mast cells (Fox et al.,
1988
). Alternatively, cromolyn may not only be blocking
histamine release in the diencephalon, mostly responsible for BBB
permeability, but also released cytokines that diffuse to other brain
areas and increase BBB permeability; cromolyn may be able to inhibit
the release of some cytokines, as it has been shown to inhibit TNF-
production from rat mast cells (Bissonnette et al., 1995
) and passively
sensitized human lung (Matsuo et al., 2000
) Nevertheless, that
99Tc extravasation in the diencephalon was
inhibited by pretreatment with site-injected cromolyn confirms that
this process requires mast cells, at least in the diencephalon. This
premise is also supported by the complete absence of any
99Tc extravasation in this region in
W/Wv mast cell-deficient mice. The diencephalon
is the brain area with the highest number of mast cells (Ibrahim, 1974
;
Pang et al., 1996
), whereas the cerebellum contains a smaller number
(Powell et al., 1999
). Mast cells are localized around the cerebral
microvasculature (Robinson-White and Beaven, 1982
) and have also been
identified close to CRH-positive neurons in the rat median eminence
(Theoharides et al., 1995
). CRH may be acting directly on mast cells,
as it was also recently shown that mast cells express CRHR-1 and -2 (Sugimoto et al., 2002
).
The involvement of mast cells in BBB permeability is also supported by
reports that the mast cell secretagogue compound 48/80 stimulated brain
mast cells in rats (Dimitriadou et al., 1990
) and in pigeons (Zhuang et
al., 1996
). Moreover, local application of 48/80 to pia-induced BBB
permeability to fluorescein-labeled dextran (Mayhan, 2000
), whereas
histamine increased BBB permeability as shown with
99mTc-sodium pertechnetate or
131I-serum albumin (Boertje et al., 1989
), as
well as by transendothelial electrical resistance in brain microvessels
(Butt and Jones, 1992
). Both histamine and serotonin may be involved in
rodents, as pretreatment with the mixed histamine/serotonin receptor
antagonist cyproheptadine inhibited BBB permeability induced by forced
swimming (Sharma et al., 1991
). The vasodilatory and proinflammatory
TNF-
(Galli, 1993
) could also be involved since this cytokine is
released along with histamine from rat hypothalamic mast cells and has
been shown to regulate BBB permeability (Kim et al., 1992
). In fact,
TNF-
was reported to be increased in the cerebrospinal fluid of MS patients (Hartung et al., 1995
), and interference with TNF function prevents encephalomyelitis (EAE) (Klinkert et al., 1997
).
The present results further our understanding of the regulation of BBB
permeability and its involvement in neuroinflammatory diseases (De
Vreis et al., 1997
). For instance, the diencephalon, where we
documented maximal BBB permeability, is involved in MS and could be a
sufficient starting point through which mast cell-derived molecules
could affect global BBB integrity (Rozniecki et al., 1995
). Breakdown
of BBB integrity has been documented to precede any clinical symptoms
or pathological findings in MS (Kermode et al., 1990
), and symptoms in
relapsing-remitting MS often appear to worsen by psychological stress
(Mei-Tal et al., 1970
; Goodin et al., 1999
). Therefore, it is relevant
that acute restraint stress significantly shortened the onset of
experimental allergic EAE in rats (Chandler et al., 2002
). EAE has been
associated with increased and activated hypothalamic mast cells
(Dimitriadou et al., 2000
), while the severity of EAE was reduced and
the onset delayed in W/Wv mast cell mice (Secor
et al., 2000
).
Our results indicate that the effect of acute stress on BBB
permeability is mediated through CRH and brain mast cells, but not that
mast cells regulate the HPA axis. In fact, recent findings indicate
that certain behavioral responses to stress still occur in CRH knockout
mice (Jacobson et al., 2000
; Muglia et al., 2001
). Nevertheless, the
mast cell secretagogue compound 48/80 was shown to increase serum
corticosterone levels through activation of hypothalamic mast cells
(Gadek-Michalska et al., 1991
). Moreover, immunologic stimulation of
hypothalamic mast cells also led to HPA axis activation and serum
corticosterone elevation (Matsumoto et al., 2001
), prompting the
speculation that mast cells may have a much more versatile role than
previously suspected (Gurish and Austen, 2001
). Mast cells could either
induce CRH release or some hypothalamic mast cell mediator could
independently activate the HPA axis. For instance, histamine and
interleukin-6 can stimulate CRH release (Kjaer et al., 1998
), and
interleukin-6 has been shown to be a CRH-independent activator of the
HPA axis (Bethin et al., 2000
). Taken together, these results indicate
that there are bidirectional actions of CRH on mast cells and such
interactions (Rozniecki et al., 1999
) could contribute in diseases
exacerbated by stress (Theoharides, 2002
).
| |
Acknowledgments |
|---|
Thanks are due to Mr. Dominic Siewko for help with timely making 99Tc available and Jerry Harmatz for assistance with the statistical analysis. We thank Dr. George Chrousos (National Institutes of Health, Bethesda, MD) for kindly supplying Antalarmin. We also thank Ms. Yahsin Tien for patience and word processing skills.
| |
Footnotes |
|---|
Accepted for publication July 16, 2002.
Received for publication May 3, 2002.
This work was supported in part by National Institutes of Health Grant NS38326 to T.C.T.
DOI: 10.1124/jpet.102.038497
Address correspondence to: Dr. T. C. Theoharides, Department of Pharmacology, and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111. E-mail: theoharis.theoharides{at}tufts.edu
| |
Abbreviations |
|---|
BBB, blood-brain barrier;
MS, multiple
sclerosis;
HPA, hypothalamic-pituitary-adrenal;
CRH, corticotropin-releasing hormone;
PVN, paraventricular nucleus;
TNF-
, tumor necrosis factor-
;
EAE, encephalomyelitis.
| |
References |
|---|
|
|
|---|
) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium.
Clin Exp Immunol
102:
78-84[Medline].
receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview.
J Neuroimmunol
72:
163-168[CrossRef][Medline].
a psychoneuroimmunological perspective.
J Clin Psychopharmacol
22:
103-108[CrossRef][Medline].This article has been cited by other articles:
![]() |
M. Larauche, S. Bradesi, M. Million, P. McLean, Y. Tache, E. A. Mayer, and J. A. McRoberts Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G1033 - G1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kern and T. Ziemssen Review: Brain immune communication psychoneuroimmunology of multiple sclerosis Multiple Sclerosis, January 1, 2008; 14(1): 6 - 21. [Abstract] [PDF] |
||||
![]() |
Z.-Q. Zhao, S. Chiechio, Y.-G. Sun, K.-H. Zhang, C.-S. Zhao, M. Scott, R. L. Johnson, E. S. Deneris, K. J. Renner, R. W. Gereau IV, et al. Mice Lacking Central Serotonergic Neurons Show Enhanced Inflammatory Pain and an Impaired Analgesic Response to Antidepressant Drugs J. Neurosci., May 30, 2007; 27(22): 6045 - 6053. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Conti, M. L. Castellani, D. Kempuraj, V. Salini, J. Vecchiet, S. Tete, F. Mastrangelo, A. Perrella, M. A. De Lutiis, M. Tagen, et al. Role of Mast Cells in Tumor Growth Ann. Clin. Lab. Sci., January 1, 2007; 37(4): 315 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kowal, L. A. DeGiorgio, J. Y. Lee, M. A. Edgar, P. T. Huerta, B. T. Volpe, and B. Diamond From the Cover: Human lupus autoantibodies against NMDA receptors mediate cognitive impairment PNAS, December 26, 2006; 103(52): 19854 - 19859. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mastorakos, E. I Karoutsou, and M. Mizamtsidi Corticotropin releasing hormone and the immune/inflammatory response Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S77 - S84. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G Papadopoulou, L. Oleson, D. Kempuraj, J. Donelan, C. L Cetrulo, and T. C Theoharides Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells J. Mol. Endocrinol., December 1, 2005; 35(3): R1 - R8. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, C. Johansen, H. Bronnum-Hansen, E. Stenager, N. Koch-Henriksen, and J. Olsen The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark Neurology, March 9, 2004; 62(5): 726 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kempuraj, N. G. Papadopoulou, M. Lytinas, M. Huang, K. Kandere-Grzybowska, B. Madhappan, W. Boucher, S. Christodoulou, A. Athanassiou, and T. C. Theoharides Corticotropin-Releasing Hormone and Its Structurally Related Urocortin Are Synthesized and Secreted by Human Mast Cells Endocrinology, January 1, 2004; 145(1): 43 - 48. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||